Windhover Announces the “Top Biopharma Projects to Watch”

Listed companies to present at Therapeutic Area Partnerships conference, Boston, November 30 - December 2

Bridgewater, NJ, November 1, 2011 –  Elsevier Business Intelligence and  Windhover Conferences today announced the  Top Projects to Watch list. The list delivers projects and companies with high-value assets for partnership, and with the potential to create future growth through investments in deals.

This year’s list includes a Top 10 in each of six therapeutic areas:cardiovascular/metabolic, oncology, neuroscience, infectious diseases and inflammatory/autoimmune, plus a “hot space” category, including ophthalmology, orphan diseases, and women’s health. The selected companies have been screened using a strict set of judging criteria, including unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications, and corporate stability. 

The top 10 projects chosen to present in each therapeutic area are selected by a panel of independent experts who screen hundreds of compounds and weigh their potential as future products. These independent experts include Campbell Alliance, NI Research, Healogix, Wolpert Associates, Cobbs Creek Healthcare and Herndon Associates. Senior business development executives from most of the major pharmaceutical firms as well as management from innovative biotechnology firms schedule one-on-one partnering meetings.

The complete list of all projects to date is available at  www.windhover.com/taprojects. Each project has been hand-selected by Windhover’s elite selection panel to ensure a high-quality slate of presenters. 

“This year’s list is handpicked in the six hottest therapeutic areas,” said David Cassak, VP, Content, for Elsevier Business Intelligence’s publications. “Many of the companies we selected in the past have gone on to do big deals, and we expect the same from this years’ companies. 90% of the companies haven’t presented at major partnering events this year.”

Attendees of the Therapeutic Area Partnerships conference benefit from expert analysis of trends and opportunities in licensing and M & A dealmaking, presentations by the industry’s foremost thought leaders and decision makers, actionable information on emerging, innovative companies and key licensable projects, strategies to finance and commercialize new products.

To register, contact Pat Cardone at +1 (203) 840-6269 p.cardone@elsevier.com or register on the Therapeutic Area Partnerships website at  www.tapartnerships.com.


###


About Windhover Conferences and Elsevier Business Intelligence
Windhover Conferences is an Elsevier Business Intelligence company, the leading provider of business intelligence and analysis to senior executives in the medical device, pharmaceutical, and biotechnology industries. Publishers of The Pink Sheet, IN VIVO: The Business & Medicine Report, PharmAsia News, The Tan Sheet",Start-Up: Emerging Medical Ventures, and The RPM Report: Regulation • Policy • Market Access, Elsevier Business Intelligence and Windhover also host a variety of industry meetings and webinars in both medical device and pharma/biotech, and produce a wide array of market research reports. For more on the companies' products and services, please visit  http://www.ElsevierBI.com.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Michael Fergus
+1 908 547 2167
M.fergus@elsevier.com